Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin

The mechanisms of action of arsenic trioxide (ATO), a clinically used drug for the treatment of acute promyelocytic leukemia (APL), have been actively studied mainly through characterization of individual putative protein targets. There appear to be no studies at a system level. Herein, we integrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xuqiao, Li, Hongyan, Ip, Tiffany Ka-Yan, Cheung, Yam Fung, Koohi-Moghadam, Mohamad, Wang, Haibo, Yang, Xinming, Tritton, Daniel N., Wang, Yuchuan, Wang, Yi, Wang, Runming, Ng, Kwan-Ming, Naranmandura, Hua, Tse, Eric Wai-Choi, Sun, Hongzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372542/
https://www.ncbi.nlm.nih.gov/pubmed/34476069
http://dx.doi.org/10.1039/d1sc03119h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372542/
https://www.ncbi.nlm.nih.gov/pubmed/34476069
http://dx.doi.org/10.1039/d1sc03119h

Ejemplares similares